HDAC9 and acute myeloid leukemia: Interfering with protein modification in AML using tyrosine kinase inhibitors, hypomethylating agents (HMAs), histone deacetylase (HDAC) inhibitors, as well as ubiquitination and SUMOylation inhibitors, has led to considerable progress in the improvement of treatment for AML.